Pancreas Cancer ScreeningNCT07012018
Pancreas Screening in High Risk Individuals
An observational study of Pancreas Cancer Screening, run by University of British Columbia.
Trial summary
Pancreas cancer is the 11th most common cancer in Canada but the 4th most common cause of cancer death because by the time pancreas cancer is detected, it is almost always too advanced for surgery. There are known factors that put individuals at higher risk for pancreas cancer. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pancreas Cancer Screening
- How many people
- 2,000 participants
- Where
- No sites listed yet
- Study dates
- Sep 2025to 31 Dec 2035
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: High risk individuals referred for pancreas screening
Who may be able to join
- Family history of pancreatic cancer, pathogenic variant increasing risk of pancreatic cancer, IPMN, new onset diabetes.
Who cannot join
- Unable to give informed consnet
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Pancreas Screening in High Risk Individuals: A Prospective Cohort
Pancreas cancer is the 11th most common cancer in Canada but the 4th most common cause of cancer death because by the time pancreas cancer is detected, it is almost always too advanced for surgery. There are known factors that put individuals at higher risk for pancreas cancer. These include: certain genetic mutations, a family history of pancreas cancer, pancreas cysts and a new diagnosis of diabetes mellitus. Individuals with these risk factors are recommended to undergo pancreas screening with blood tests and yearly imaging tests of the pancreas. Our study will enroll patients with these risk factors and ensure they are managed as per guidelines. Prospectively collected data will include: patient clinicodemographic details, lifestyle factors, screening test results, clinical outcomes and patient reported outcome measures.
- Conditions
- Pancreas Cancer Screening
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| High risk individuals for pancreas cancer | Individuals undergoing pancreas screening |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of pancreatic cancer
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2025
- Study startSep 2025 (estimated)
- Primary completion31 Dec 2035 (estimated)
- Study completion31 Dec 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreas Cancer ScreeningStudies of the same condition, open and under way.
- More trials run by University of British ColumbiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of British Columbia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jennifer Telford, University of British Columbia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07012018
- Sponsor's protocol ID
- H25-01796
- Status last verified
- Jun 2025
- First submitted
- 2 Jun 2025
- Last updated
- 10 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pancreas Screening in High Risk Individuals: A Prospective Cohort
- ClinicalTrials.gov ID
- NCT07012018
- Acronym / sponsor ID
- H25-01796
- Conditions
- Pancreas Cancer Screening
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- University of British ColumbiaUniversity, hospital or other
- Study start
- Sep 2025 (estimated)
- Primary completion
- 31 Dec 2035 (estimated)
- Study completion
- 31 Dec 2035 (estimated)
- First posted
- 10 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pancreas cancer is the 11th most common cancer in Canada but the 4th most common cause of cancer death because by the time pancreas cancer is detected, it is almost always too advanced for surgery. There are known factors that put individuals at higher risk for pancreas cancer. These include: certain genetic mutations, a family history of pancreas cancer, pancreas cysts and a new diagnosis of diabetes mellitus. Individuals with these risk factors are recommended to undergo pancreas screening with blood tests and yearly imaging tests of the pancreas. Our study will enroll patients with these risk factors and ensure they are managed as per guidelines. Prospectively collected data will include: patient clinicodemographic details, lifestyle factors, screening test results, clinical outcomes and patient reported outcome measures.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| High risk individuals for pancreas cancer | – | –Individuals undergoing pancreas screening |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- High risk individuals referred for pancreas screening
Key inclusion criteria (1 listed)
- Family history of pancreatic cancer, pathogenic variant increasing risk of pancreatic cancer, IPMN, new onset diabetes.
Key exclusion criteria (1 listed)
- Unable to give informed consnet
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Incidence of pancreatic cancer
Time frame: 10 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jun 2025.
- Individual participant dataSharing planned: No
Related trials for Pancreas Cancer Screening
RecruitingObservational study
Pancreatic Cancer Early Detection Consortium
Pancreas Cancer, Pancreas Cyst
RecruitingObservational study
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Recruiting
Pancreatic Cancer Screening Using the Enzeavour Assay in Japan
Pancreatic Cancer, Pancreatic Neoplasms
Active, not recruitingPhase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Recruiting
Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial
Pancreatic Ductal Adenocarcinoma (PDAC), Family History of Pancreas Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Pancreas Cancer Screening, run by University of British Columbia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 10 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jennifer Telford, MD MPH (1-604-688-6332 ext. 254, jtelford@telus.net), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of pancreatic cancer (time frame: 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2025.